Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review

Simple item page
dc.contributor.authorCairns, K.A.
dc.contributor.authorHall, V.
dc.contributor.authorMartin, G.E.
dc.contributor.authorGriffin, D.W.J.
dc.contributor.authorStewart, J.D.
dc.contributor.authorKhan, S.F.
dc.contributor.authorAbbott, I.J.
dc.contributor.authorMeher-Homji, Z.
dc.contributor.authorMorrissey, C.O.
dc.contributor.authorSia, C.
dc.contributor.authorLove, J.
dc.contributor.authorCorallo, C.E.
dc.contributor.authorBergin, P.
dc.contributor.authorSharma, A.
dc.contributor.authorGopal, B.
dc.contributor.authorSpencer, A.
dc.contributor.authorPeleg, A.Y.
dc.date.issued2020
dc.description.abstractInfections caused by carbapenemase-producing Enterobacteriaceae (CPE) are an emerging threat in both solid organ and stem cell transplant recipients. Invasive CPE infections in transplant recipients are associated with a high mortality, often due to limited therapeutic options and antibacterial toxicities. One of the most therapeutically challenging group of CPE are the metallo-β-lactamase (MBL)-producing Gram-negative bacteria, which are now found worldwide, and often need treatment with older, highly toxic antimicrobial regimens. Newer β-lactamase inhibitors such as avibactam have well-established activity against certain carbapenemases such as Klebsiella pneumoniae carbapenemases (KPC), but have no activity against MBL-producing organisms. Conversely, aztreonam has activity against MBL-producing organisms but is often inactivated by other co-existing β-lactamases. Here, we report four cases of invasive MBL-CPE infections in transplant recipients caused by IMP-4-producing Enterobacter cloacae who were successfully treated with a new, mechanism-driven antimicrobial combination of ceftazidime/avibactam with aztreonam. This novel antimicrobial combination offers a useful treatment option for high-risk patients with CPE infection, with reduced drug interactions and toxicity.
dc.description.statementofresponsibilityKelly A. Cairns, Victoria Hall, Genevieve E. Martin, David W.J. Griffin, James D. Stewart, Sadid F. Khan ... et al.
dc.identifier.citationTransplant Infectious Disease, 2020; 23(2):1-10
dc.identifier.doi10.1111/tid.13510
dc.identifier.issn1398-2273
dc.identifier.issn1399-3062
dc.identifier.orcidGopal, B. [0000-0002-8586-8743]
dc.identifier.urihttp://hdl.handle.net/2440/130943
dc.language.isoen
dc.publisherWiley
dc.rights© 2020 Wiley Periodicals LLC.
dc.source.urihttps://doi.org/10.1111/tid.13510
dc.subjectE. cloacae
dc.subjectMBL
dc.subjectantimicrobial resistance
dc.subjectantimicrobials
dc.subjectmetallo-beta-lactamase
dc.titleTreatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications